Literature DB >> 3821943

Can exercise-induced regional contractile dysfunction be prevented by selective bradycardic agents?

G Krumpl, W Schneider, G Raberger.   

Abstract

Propranolol (0.5 mg X kg-1 X 5 min-1), alinidine (1 mg X kg-1 X 5 min-1) and the benzazepinon UL-FS 49 (0.5 mg X kg-1 X 5 min-1) were investigated in a canine model of exercise-induced transient myocardial dysfunction, mimicking exercise-induced functional impairment during angina pectoris in man. Each drug was infused intravenously, after two control treadmill exercise runs had shown comparable, ultrasonically assessed regional contractile dysfunction in an area supplied by a partly stenosed branch of the left coronary artery. All three drugs abolished exercise-induced regional contractile dysfunction. Propranolol and alinidine comparably decreased heart rate and positive dp/dtmax during exercise. UL-FS 49 showed a marked negative chronotropic effect without affecting positive dp/dtmax. Thus, prevention of exercise-induced regional contractile dysfunction has been shown for the first time using a selective bradycardic agent.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3821943     DOI： 10.1007/bf00569399

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN： 0028-1298            Impact factor:   3.000


  10 in total

1.  Investigations into the bradycardic effects of UL-FS 49 (1,3,4,5-tetrahydro-7,8-dimethoxy-3-[3-[[2-(3,4-dimethoxyphenyl)ethyl] methylimino]propyl]-2H-3-benzazepin-2-on-hydrochloride) in isolated guinea pig atria.

Authors:  C Lillie; W Kobinger
Journal:  J Cardiovasc Pharmacol       Date:  1986 Jul-Aug       Impact factor: 3.105

2.  Alinidine, a new agent which lowers heart rate in patients with angina pectoris.

Authors:  M L Simoons; J Tummers; H van Meurs-van Woezik; R van Domburg
Journal:  Eur Heart J       Date:  1982-12       Impact factor: 29.983

3.  Reduction of exercise-induced regional myocardial dysfunction by propranolol. Studies in a canine model of chronic coronary artery stenosis.

Authors:  T Kumada; K P Gallagher; K Shirato; D McKown; M Miller; W S Kemper; F White; J Ross
Journal:  Circ Res       Date:  1980-02       Impact factor: 17.367

4.  N-Allyl-derivative of clonidine, a substance with specific bradycardic action at a cardiac site.

Authors:  W Kobinger; C Lillie; L Pichler
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1979-04       Impact factor: 3.000

5.  A model of transient myocardial dysfunction in conscious dogs. Regional shortening in the presence of impaired coronary flow reserve and treadmill exercise.

Authors:  G Raberger; G Krumpl; N Mayer
Journal:  J Pharmacol Methods       Date:  1986-08

6.  Alinidine in angina.

Authors:  T Meinertz; W Kasper; R Meier; U Wiegand; H Bechtold; I Förster; T Pop; E Jähnchen
Journal:  Clin Pharmacol Ther       Date:  1983-12       Impact factor: 6.875

7.  [Hemodynamic actions on alinidine during exercise in patients with coronary artery disease].

Authors:  H Löllgen; H Just; H Wollschläger; F Kersting
Journal:  Z Kardiol       Date:  1981-05

8.  Bepridil abolishes exercise-induced regional contractile dysfunction in dogs.

Authors:  G Krumpl; N Mayer; W Schneider; G Raberger
Journal:  Int J Cardiol       Date:  1986-07       Impact factor: 4.164

9.  Anion-channel blockade with alinidine: a specific bradycardic drug for coronary heart disease without negative inotropic activity?

Authors:  B E Jaski; P W Serruys
Journal:  Am J Cardiol       Date:  1985-08-01       Impact factor: 2.778

10.  Cardiovascular characterization of UL-FS 49, 1,3,4,5-tetrahydro-7,8-dimethoxy-3-[3-][2-(3,4-dimethoxyphenyl)ethyl] methylimino]propyl]-2H-3-benzazepin-2-on hydrochloride, a new "specific bradycardic agent".

Authors:  W Kobinger; C Lillie
Journal:  Eur J Pharmacol       Date:  1984-09-03       Impact factor: 4.432
  10 in total
  7 in total

1.  Electrophysiological effects of S 16257, a novel sino-atrial node modulator, on rabbit and guinea-pig cardiac preparations: comparison with UL-FS 49.

Authors:  C Thollon; C Cambarrat; J Vian; J F Prost; J L Peglion; J P Vilaine
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

2.  On the mechanism of the "specific bradycardic action" of the verapamil derivative UL-FS 49.

Authors:  T Doerr; W Trautwein
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-04       Impact factor: 3.000

3.  Electropharmacology of the bradycardic agents alinidine and zatebradine (UL-FS 49) in a conscious canine ventricular arrhythmia model of permanent coronary artery occlusion.

Authors:  I Aidonidis; J Brachmann; I Rizos; A Zacharoulis; I Stavridis; P Toutouzas; W Kübler
Journal:  Cardiovasc Drugs Ther       Date:  1995-08       Impact factor: 3.727

Review 4.  Effect of a bradycardic agent on the isolated blood-perfused canine heart.

Authors:  J D Schipke; Y Harasawa; S Sugiura; J Alexander; D Burkhoff
Journal:  Cardiovasc Drugs Ther       Date:  1991-04       Impact factor: 3.727

5.  The effects of nitroglycerin on regional myocardial contractile dysfunction produced by treadmill exercise or isoprenaline stimulation in dogs.

Authors:  W Schneider; J G Grohs; G Krumpl; N Mayer; G Raberger
Journal:  Br J Pharmacol       Date:  1988-12       Impact factor: 8.739

6.  Comparison of the haemodynamic effects of the selective bradycardic agent UL-FS 49, with those of propranolol during treadmill exercise in dogs.

Authors:  G Krumpl; M Winkler; W Schneider; G Raberger
Journal:  Br J Pharmacol       Date:  1988-05       Impact factor: 8.739

7.  Population Pharmacokinetic Data Analysis of Cilobradine, an I f Channel Blocker.

Authors:  Gabriele Fliss; Alexander Staab; Christiane Tillmann; Dirk Trommeshauser; Hans G Schaefer; Charlotte Kloft
Journal:  Pharm Res       Date:  2007-06-21       Impact factor: 4.200
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.